Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Leases: 2019-2024

Historic Operating Leases for Northwest Biotherapeutics (NWBO) over the last 6 years, with Dec 2024 value amounting to $4.4 million.

  • Northwest Biotherapeutics' Operating Leases fell 7.89% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 7.89%. This contributed to the annual value of $4.4 million for FY2024, which is 0.36% down from last year.
  • As of FY2024, Northwest Biotherapeutics' Operating Leases stood at $4.4 million, which was down 0.36% from $4.5 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Operating Leases registered a high of $5.2 million during FY2021, and its lowest value of $4.4 million during FY2022.
  • Its 3-year average for Operating Leases is $4.4 million, with a median of $4.4 million in 2024.
  • Its Operating Leases has fluctuated over the past 5 years, first rose by 6.31% in 2021, then declined by 16.38% in 2022.
  • Northwest Biotherapeutics' Operating Leases (Yearly) stood at $4.9 million in 2020, then grew by 6.31% to $5.2 million in 2021, then fell by 16.38% to $4.4 million in 2022, then grew by 1.92% to $4.5 million in 2023, then decreased by 0.36% to $4.4 million in 2024.